J&J, Sanofi and Escherichia coli

J&J stops Phase III trial of Sanofi’s E. Coli vaccine citing ‘disappointing’ results
The company said it will stop the Phase III trial of ExPEC after interim results found it failed to demonstrate efficacy over placebo.
Sanofi, J&J abandon trial of E coli vaccine after poor data
Johnson & Johnson and Sanofi's vaccine for preventing invasive disease caused by the problem pathogen Escherichia coli looks all but defunct after the two partners halted a phase 3 trial.
J&J, Sanofi stop E.coli vaccine trial due to low effectiveness
Johnson & Johnson and partner Sanofi will stop a late-stage trial of an experimental vaccine to prevent infections caused by the E.coli bacteria due to a lack of sufficient efficacy, the companies said on Thursday.
Sanofi Ends E.coli Vaccine Trial Amid Efficacy Concerns
Sanofi ( ($SNY) ) has provided an announcement. On February 13, 2025, Sanofi announced the discontinuation of the E.mbrace phase 3 study for its
Johnson & Johnson halts late-stage E.coli vaccine trial after poor results
Pharmaceutical giants Johnson & Johnson and Sanofi have stopped a late-stage clinical trial for their experimental E.coli vaccine after results failed to demonstrate sufficient efficacy. The companies announced on Thursday that while the vaccine showed no safety concerns,
J&J to discontinue E.coli vaccine candidate study
Johnson & Johnson said on Thursday it will discontinue a late-stage study of an experimental E.coli vaccine it was developing in partnership with Sanofi. The drugmaker said its decision was based on t
Tackling the threat of drug-resistant E. coli in China
A comprehensive seven-year study across 20 Chinese provinces has revealed a concerning rise in antimicrobial resistance (AMR) ...
Expert: E. coli infection among doctors at Hong Kong hospital ‘unlikely to spread widely’
An E coli infection linked to the death of a doctor in Princess Margaret Hospital is unlikely to lead to widespread ...
GEN17h
Antibiotic Resistance Linked to Extra Pump Proteins in Gram-Negative Bacteria
By analyzing E. coli protein levels, scientists found a surplus of membrane shuttle proteins that may play a role in ...
Scientists develop magnesium-enriched nanofiber patches for safer wound healing
The skin serves as the body's primary defense against harmful microorganisms, toxins, and physical damage. However, severe ...
Nature3d
A bacterial antiviral system detects and directly fights against infection
Protein complex in bacterial cell membrane acts like a rotary motor to recruit DNA-degrading enzymes to defend against phage ...
Food Safety News6d
Publisher’s Platform: Combating E. coli — A call for vigilance in food safety practices
Escherichia coli, commonly known as E. coli, is a versatile bacterium. While many strains are harmless and a natural part of our intestinal ...
Bacterial species study challenges assumption that structural similarity predicts protein behavior
A new study published in Biochemistry sheds light on how bacteria regulate their genes, challenging long-held assumptions ...
香港政府新聞網3d
Suspected E. coli cluster probed
The Centre for Health Protection is looking into a suspected Shiga toxin-producing Escherichia coli infection cluster ...
Suspected GBS deaths in Maharashtra rise to 4, case tally at 140; E.coli found in water sample
Suspected Guillain-Barré Syndrome (GBS) deaths in Maharashtra rise to four, with E.coli found in water samples in Pune.
Renal & Urology News1d
Emblaveo Approved for Intra-Abdominal Infections in Patients With Limited Options
The FDA has approved Emblaveo with metronidazole for patients with complicated intra-abdominal infections and limited options.